文献速递白血病

整合核蛋白质组与转录组分析确定S100A4为急性髓系白血病治疗靶点

Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2019-10-14

该研究比较了急性髓系白血病(AML)原始细胞与正常人造血干祖细胞的核蛋白质组和转录组,发现蛋白质与mRNA水平变化不具预测一致性,S100A4是AML细胞核中差异表达最高的蛋白,在扩展队列中83%(20/24)的AML患者核内S100A4过表达,敲低S100A4可显著影响AML细胞系存活而不影响正常造血干祖细胞。

要点

  • AML核蛋白质组与转录组变化不一致,转录因子蛋白水平改变无法由mRNA预测。
  • S100A4在83%(20/24)的AML患者核内过表达,为差异最显著的核蛋白。
  • 敲低S100A4显著降低AML细胞系存活,正常造血干祖细胞不受影响。

核心结论

  • S100A4对AML细胞存活至关重要,可能成为AML的治疗靶点。

研究设计与样本

  • 研究比较了AML原始细胞与正常人CD34+细胞的核蛋白质组和转录组,并在扩展队列中验证S100A4表达。

主要发现

  • 蛋白质组分析发现11个转录因子异常表达,其中7个蛋白此前未在AML中报道。
  • 转录组分析鉴定出40个转录因子变化,但均不能预测蛋白质水平改变。
  • AML细胞核中S100A4差异表达最高,且此前未在AML中报道。
  • 扩展队列中83%(20/24)的AML患者核内S100A4过表达。
  • 敲低S100A4显著影响AML细胞系存活,而正常造血干祖细胞不受影响。

临床怎么用

  • 核内S100A4过表达可作为AML潜在治疗靶点的依据,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inappropriate localization of proteins can interfere with normal cellular function and drive tumor development. To understand how this contributes to the development of acute myeloid leukemia (AML), we compared the nuclear proteome and transcriptome of AML blasts with normal human CD34+ cells. Analysis of the proteome identified networks and processes that significantly affected transcription regulation including misexpression of 11 transcription factors with seven proteins not previously implicated in AML. Transcriptome analysis identified changes in 40 transcription factors but none of these were predictive of changes at the protein level. The highest differentially expressed protein in AML nuclei compared with normal CD34+ nuclei (not previously implicated in AML) was S100A4. In an extended cohort, we found that over-expression of nuclear S100A4 was highly prevalent in AML (83%; 20/24 AML patients). Knock down of S100A4 in AML cell lines strongly impacted their survival whilst normal hemopoietic stem progenitor cells were unaffected. These data are the first analysis of the nuclear proteome in AML and have identified changes in transcription factor expression or regulation of transcription that would not have been seen at the mRNA level. These data also suggest that S100A4 is essential for AML survival and could be a therapeutic target in AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Alanazi B, Munje CR, Rastogi N, et al. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia. 2019. PMID: 31611628. doi:10.1038/s41375-019-0596-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。